A real-world study of sorafenib and lenvatinib: A retrospective review of multikinase inhibitor therapies for hepatocellular carcinoma in an Australian tertiary treatment center

被引：0
|
作者：
Patwala, K. [1 ]
Alam, W. [1 ]
Ng, S. [1 ]
O'Neill, P. [1 ]
Mishra, G. [1 ]
Bell, S. [1 ]
Dev, A. [1 ,2 ]
机构：
[1] Monash Hlth, Melbourne, Vic, Australia
[2] Monash Univ, Melbourne, Vic, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2020年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
368
引用
收藏
页码：97 / 98
页数：2
相关论文
共 50 条
  • [21] Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
    Kuo, Yuan-Hung
    Lu, Sheng-Nan
    Chen, Yen-Yang
    Kee, Kwong-Ming
    Yen, Yi-Hao
    Hung, Chao-Hung
    Hu, Tsung-Hui
    Chen, Chien-Hung
    Wang, Jing-Houng
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [22] Real-world experience of atezolizumab and bevacizumab for treatment of advanced hepatocellular carcinoma in a single tertiary center
    Raharjo, C. V.
    Joseph, R.
    Stratton, E.
    Levy, M.
    Prakoso, E.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 22 - 22
  • [23] Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population
    Lee, Shou-Wu
    Yang, Sheng-Shun
    Lien, Han-Chung
    Peng, Yen-Chun
    Ko, Chung-Wang
    Lee, Teng-Yu
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (05)
  • [24] Transarterial chemoembolization combined with donafenib or lenvatinib as first-line treatment for unresectable hepatocellular carcinoma: A single-center real-world retrospective study.
    Liu, Huan
    Huang, Mingsheng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] Letter to the editor on "Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/ bevacizumab failure: A real-world study"
    Wu, Meng-Che
    Chang, Hui-Chin
    Jhang, Yi-Sheng
    Gau, Shuo-Yan
    CLINICAL AND MOLECULAR HEPATOLOGY, 2025, 31 (01)
  • [26] Sorafenib Versus Lenvatinib-Based Sequential Systemic Therapy for Advanced Hepatocellular Carcinoma: A Real-World Analysis
    Leyh, Catherine
    Ehmer, Ursula
    Roessler, Daniel
    Philipp, Alexander B.
    Reiter, Florian P.
    Jeliazkova, Petia
    Jochheim, Leonie S.
    Jeschke, Matthias
    Hammig, Janina
    Ludwig, Johannes M.
    Theysohn, Jens M.
    Geier, Andreas
    Lange, Christian M.
    CANCERS, 2022, 14 (08)
  • [27] Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study
    Zhao, Lei
    Chang, Niajia
    Shi, Lei
    Li, Fengyi
    Meng, Fanglin
    Xie, Xiaohui
    Xu, Zhe
    Wang, Fusheng
    HELIYON, 2022, 8 (06)
  • [28] Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
    Chiang, Hsueh-Chien
    Lee, Yang-Cheng
    Chang, Ting-Tsung
    Lin, Yih-Jyh
    Wu, Hung-Tsung
    Wang, Chung-Teng
    Chen, Chiung-Yu
    Chen, Po-Jun
    Hsieh, Ming-Tsung
    Lin, Sheng-Hsiang
    Chen, Shang-Hung
    Chuang, Chiao-Hsiung
    Wu, I-Chin
    Hong, Tzu-Chun
    Wu, Juei-Seng
    Han, Meng-Zhi
    Chen, Wei-Ting
    Chiang, Chien-Ming
    Hung, Kuan-Kai
    Kuo, Hsin-Yu
    CANCERS, 2023, 15 (03)
  • [29] Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea
    Min Jin Lee
    Sung Won Chang
    Ji Hoon Kim
    Young-Sun Lee
    Sung Bum Cho
    Yeon Seok Seo
    Hyung Joon Yim
    Sang Youn Hwang
    Hyun Woong Lee
    Young Chang
    Jae Young Jang
    Investigational New Drugs, 2021, 39 : 260 - 268
  • [30] Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea
    Lee, Min Jin
    Chang, Sung Won
    Kim, Ji Hoon
    Lee, Young-Sun
    Cho, Sung Bum
    Seo, Yeon Seok
    Yim, Hyung Joon
    Hwang, Sang Youn
    Lee, Hyun Woong
    Chang, Young
    Jang, Jae Young
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (01) : 260 - 268
12345